Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 2, 2006, Pages 515-517

  Morales, L ^a   Timmerman, D ^a   Neven, P ^a   Paridaens, R ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Aromatase inhibitors; Breast cancer; Endometrium; Tamoxifen; Uterine changes

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

BREAST CANCER; CANCER PATIENT; CONFERENCE PAPER; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIAL THICKENING; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM CYST; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ESTROGEN ACTIVITY; HUMAN; PRIORITY JOURNAL; RISK; TUMOR GROWTH; TUMOR VOLUME; UTERINE ATROPHY; UTERUS; UTERUS DISEASE; UTERUS MYOMA; UTERUS SARCOMA;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; POSTMENOPAUSE; TAMOXIFEN; UTERINE DISEASES;

EID: 33748778200     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00555.x     Document Type: Conference Paper

References (20)

1. Neven P, De Muylder X, Van Belle Y et al. Tamoxifen and the uterus and endometrium. Lancet 1989;i:375.
2. Kedar RP, Bourne TH, Powles TJ et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318-21.
3. Fisher B, Constantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
4. Jordan VC. Tamoxifen for the treatment and prevention of breast cancer. Melville, NY: PRR Inc, 1999:117-26.
5. Wickerham DL, Fisher B, Wolmark N et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002;20:2758-60.
6. Neven P, Vergote I. Should tamoxifen users be screened for endometrial lesions? Lancet 1998;351:155-7.
7. Goss PE. Risk versus benefits in the clinical application of aromatase inhibitors. Endocr Relat Cancer 1999;6:325-32.
8. Dowsett M. Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. Semin Oncol 2003;30:58-69.
9. Gradishar W. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 2005;69:1-9.
10. Morales L, Neven P, Paridaens R. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 2005;17:559-65.
11. The ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
12. Goss P, Ingle J, Martino S et al. A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1-10.
13. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350: 1081-92.
14. Morales L, Timmerman D, Neven P et al. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 2005;16:70-4.
15. Duffy S, Jackson TL, Lansdown M et al. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21:545-53.
16. Bertelli G, Hall E, Bliss JM et al. Intergroup Exemestane Study: results of the endometrial sub-protocol [abstract]. Breast Cancer Res Treat 2004;88(Suppl. 1):S35. Abstract 402.
17. Garrone O, Mezi S, Occelli M et al. Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients: a prospective TVUS study. Ann Oncol 2003;14(Suppl. 4). Abstract A22.
18. Paridaens R, Thomas J, Wildiers J et al. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anticancer Drugs 1998;9:675-83.
19. Dowsett M, Jones A, Johnston SRD et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995;1:1511-5.
20. Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286-91.